Dados do Resumo
Título
SERUM PROFILE OF PRO-INFLAMMATORY CYTOKINES IN PATIENTS WITH COLORECTAL CANCER
Introdução
Colorectal cancer (CRC) is one of the most prevalent neoplasms worldwide. At a national level, projections for the years 2023 to 2025 indicate the occurrence of approximately 45,630 cases. Based on the National Cancer Institute. The main components of these cytokines are mediators of inflammation and modulators of different types of antitumor responses However, these molecules can also have adverse effects on tumor progression, depending on the patient's immune status.
Objetivo
Describe the profile of pro-inflammatory cytokines in patients with colorectal cancer. As well as quantifying the circulating levels of pro-inflammatory cytokines such as Interleukin (IL)-1β, IL-6, IL-8, IL-12 and TNF-α and the anti-inflammatory mediator cytokine (IL)-10.
Métodos
A prospective longitudinal observational study included 106 participants treated between 2022 and 2024. The inclusion criteria for the individuals are: diagnosis of colorectal adenocarcinoma with ICD: 18, 19 and 20, who had not received previous treatments in the region of the tumor, such as surgery, chemotherapy or radiotherapy, and who were aged 18 or over. Exclusion criteria are insufficient or inadequately preserved biological samples. All participants were asked to sign an informed consent form (ICF). A structured form was used to collect clinical data, and the information was organized into spreadsheets for subsequent statistical analysis. For molecular evaluation, 10 ml of peripheral blood were collected at the time of diagnosis (T0). The quantification and kinetic analysis of cytokines were performed by flow cytometry using the Cytometric Beads Array (CBA).
Resultados
This study explores serum concentrations of pro-inflammatory interleukin (IL-6, IL-8, IL-12, IL-1β and TNF) in comparison to the anti-inflammatory interleukin mediator IL-10, which inhibits pro-inflammatory cytokines. . IL-6 and IL-8 are difficult to inhibit in chronic inflammation due to distinct signaling pathways. Selective JAK-STAT inhibitors paradoxically increase IL-6 production by blocking IL-10-mediated feedback inhibition. IL-12, IL-1β and TNF, which do not share the IL-10 signaling pathway, are inhibited by different regulatory mechanisms. IL-10 interferes with the NF-κB pathway, which is crucial for the activation of many pro inflammatory genes, including IL-12 and TNF. IL-1β activity is reduced by IL-10, which decreases NLRP3 activity, thereby inhibiting IL-1β maturation. Study participants predominantly comprised women (66), compared to men (40), with an average age of 61 years. The reason for this gender disparity is still unknown.
Conclusões
This study is part of a larger project that is under development. More research is needed on cytokines in patients with color rectal cancer to understand their interactions and mechanisms of action and inhibition in cancer. Regarding ethical aspects, the study was approved under the title “Analysis of the Molecular and Clinical Spectrum of Colorectal Cancer: from Epidemiology and Quality of Life to Genetic and Omic Analysis” (CAAE: 52343821.2.0000.0004, Opinion Number: 5.150.654/ 2021).
Financiador do resumo
FAPEAM – Programa PAIC 23/24;
Palavras Chave
Câncer Colorretal; Citocinas; Citometria de Fluxo
Área
9.Outros (Temas não mencionados acima, Relatos de Casos e Revisão de literatura)
Autores
IGOR SAMUEL GADELHA DA SILVA, Valquíria do Carmo Alves Martins, Kátia Luz Torres Silva, José Fernando Marques Barcellos , José Fernando Marques Barcellos , Jhonnatan Silva de Souza, Allyson Guimarães da Costa, Ábner Souza Paz, Elias de Souza Barro, Mateus de Souza Barros, Ryanna dos Santos Amarro, Antonio Gabriel Martins Maciel, Ana Elis Guimarães Araujo, Júlia Mônica Marcelino Benevides